ArticleAmerican journal of cancer research2026
Pulsatilla decoction attenuates colorectal cancer progression in association with gut microbiota remodeling, T-cell immune restoration, and NF-κB/JAK2/STAT3 signaling suppression.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulsatilla Decoction (PD) exhibits anti-inflammatory properties, but its impact on colorectal cancer (CRC) and the role of gut microbiota remain incompletely understood. This study investigated the antitumor effects of PD in a xenograft mouse model of HCT116 cells reconstituted with human peripheral blood mononuclear cells. We also analyzed corresponding changes in gut microbiota, T-cell immunity, inflammatory responses, and NF-κB/JAK2/STAT3 signaling. Tumor-bearing mice were treated for three weeks with low-, medium-, or high-dose PD, or with 5-fluorouracil. Gut microbiota composition and function were analyzed using 16S rRNA and metagenomic sequencing. Immune cell populations, cytokines, and pathway-related proteins were assessed via flow cytometry, immunofluorescence, ELISA, RT-qPCR, and western blotting. To further evaluate the involvement of microbiota, we performed antibiotic pretreatment followed by fecal microbiota transplantation (FMT). PD effectively reduced tumor volume and weight without causing significant body weight loss. High-dose PD partially restored microbial diversity and community structure, increased Akkermansia muciniphila, and modulated inflammation- and metabolism-related microbial pathways. Furthermore, PD enhanced peripheral and intratumoral CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.